Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan plus PD-1 inhibitor in advanced non-squamous NSCLC
2024-514465-18-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-limiting toxicity and Objective response rate. Planned start Apr 2025; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-514465-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514465-18-00.